ASH 2021
ASH 2021
Advertisement
Ariel JonesCancer | January 20, 2023
Pirtobrutinib, a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, showed promising efficacy in patients with ...
Read More
Ariel JonesCancer | December 14, 2022
A fixed-duration combination of the first-generation Bruton tyrosine kinase (BTK) inhibitor ibrutinib and the ...
Ariel JonesCancer | January 3, 2023
Second-line therapy comprising standard rituximab plus bendamustine and bortezomib was effective and well-tolerated as ...
Ariel JonesMultiple Myeloma | October 17, 2023
The trial was conducted by Dr. Malin Hultcrantz and colleagues, and presented at the 2021 American Society of Hematology.
Ariel JonesCancer | January 3, 2023
A phase II study presented at the 2021 Annual Meeting & Exposition of the American Society of Hematology, reported ...
Ariel JonesCancer | January 3, 2023
The all-oral, once-daily, fixed-duration combination of ibrutinib and venetoclax demonstrated superior undetectable MRD ...
Ariel JonesMultiple Myeloma | October 17, 2023
In the iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) study, researchers explored whether ...
Ariel JonesMultiple Myeloma | October 17, 2023
These results were presented at the 2021 American Society of Hematology Annual Meeting.
Urban Health Today EditorsASH 2021 | October 17, 2023
The three-drug combination was previously investigated in the CASTOR trial.
Urban Health Today EditorsASH 2021 | October 17, 2023
The study’s results may lay the groundwork for the development of a patient-centered frailty index.
Urban Health Today EditorsASH 2021 | May 5, 2023
Brexucabtagene autoleucel (brexu-cel) has been implemented into standard MCL care since its 2020 FDA approval.
Urban Health Today EditorsCancer | January 20, 2023
Researchers developed a virtual frailty assessment for older adults with hematologic malignancies and found no evidence ...
Urban Health Today EditorsMultiple Myeloma | October 17, 2023
Nearly half of new diagnosed of multiple myeloma (MM) and non-Hodgkin lymphoma (NHL) are in patients over 75 years old.
Urban Health Today EditorsMultiple Myeloma | October 17, 2023
This retrospective study reviewed charts of patients with MM initiating daratumumab from January 2018 to May 2020.
Urban Health Today EditorsMultiple Myeloma | October 17, 2023
It is not clear if differences in diagnostic evaluation lead to differences in treatment strategies and survival outcomes.
Urban Health Today EditorsMultiple Myeloma | October 17, 2023
Socioeconomic status (SES) accounted for disparities in survival time between Hispanic and non-Hispanic White patients ...
Urban Health Today EditorsMultiple Myeloma | October 17, 2023
An analysis of data from the CoMMpass trial revealed no obvious differences in significant measures of genomic variation ...
Urban Health Today EditorsMultiple Myeloma | October 17, 2023
Enrollment of ethnic minorities into academic clinical trials of multiple myeloma (MM) in the United Kingdom was below ...
Urban Health Today EditorsMultiple Myeloma | February 1, 2024
A study of individuals with multiple myeloma (MM) revealed significant racial disparities in the prevalence of obesity ...
Urban Health Today EditorsASH 2021 | May 5, 2023
The analysis was a retrospective cohort analysis of 32 consecutive WM patients treated with ASCT.
Advertisement
Advertisement
Advertisement
Latest News

December 12, 2024